Publications Team 3 – INSERM UMR 1033

Bone and Joint Pathophysiology: Bioactive lipids and mineral metabolism

Top 10 publications over the past 6 years

1. Groothoff JW, Metry E, Deesker L, Garrelfs S, Acquaviva C, Almardini R, Beck BB, Boyer O, Cerkauskiene R, Ferraro PM, Groen LA, Gupta A, Knebelmann B, Mandrile G, Moochhala SS, Prytula A, Putnik J, Rumsby G, Soliman NA, Somani B, Bacchetta J. (2023) Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope. Nature Reviews: Nephrology;19(3):194-211.
2. Méaux MN*, Alioli C*Linglart A, Lemoine S, Vignot E, Bertholet-Thomas A, Peyruchaud O, Flammier S, Machuca-Gayet I, Bacchetta J. (2022) X-linked hypophosphatemia, not only a skeletal disease but also a chronic inflammatory state. Journal of Clinical Endocrinology and Metabolism. Epub 20220916. doi: 10.1210/clinem/dgac543. PubMed PMID: 36112422.
3. Saier L, Ribeiro R, Daunizeau T, Houssin A, Ichim G, Barette C, Bouazza L, Peyruchaud O. (2022) Blockade of Platelet CysLT1R Receptor with Zafirlukast Counteracts Platelet Protumoral Action and Prevents Breast Cancer Metastasis to Bone and Lung. International Journal of Molecular Science. 23(20):12221. doi: 10.3390/ijms232012221.
4. Cornille M, Moriceau S, Khonsari RH, Heuzé Y, Loisay L, Boitez V, Morice A, Arnaud E, Collet C, Bensidhoum M, Kaci N, Boddaert N, Paternoster G, Rauschendorfer T, Werner S, Mansour SL, Di Rocco F, Oury F, Legeai-Mallet L. (2022) FGFR3 overactivation in the brain is responsible for memory impairments in Crouzon syndrome mouse model. Journal of Experimental Medicine. (2022) Apr 4;219(4):e20201879. doi: 10.1084/jem.20201879. Epub 2022 Mar 7. PMID: 35254402
5. Quinaux T, Bertholet-Thomas A, Servais A, Boyer O, Vrillon I, Hogan J, Lemoine S, Gaillard S, Alioli C, Vasseur S, Acquaviva-Bourdain C, Peyruchaud O, Machuca-Gayet I, Bacchetta J. (2021) Response to cysteamine in osteoclasts obtained from patients with nephropathic cystinosis: a genotype/phenotype correlation. Cells. 10(9):2498-2513. (doi: 10.3390/cells10092498.).
6. Alioli C*, Demesmay L*, Laurencin S, Beton N, Farlay D, Follet H, Chun J, Rivera R, Bouvard D, Machuca-Gayet I,  Salles JP, Gennero I and Peyruchaud O. (2020) Expression of the type 1 lysosphosphatidic acid receptor in osteoblastic cell lineage controls bone mineralization and osteocyte specification. BBA Molecular Biology of Lipids. 1865(8):158715.
7. Bernardor J, Flammier S, Ranchin B, Gaillard S, Platel D, Peyruchaud O, Machuca-Gayet I, Bacchetta J. (2020) Inhibition of osteoclast differentiation by 1.25-D and the calcimimetic KP2326 reveals 1.25-D resistance in advanced CKD. Journal of Bone and Mineral Research. 35 (11): 2265-2274.
8. Flammier S, Peyruchaud O, Bourguillaut F, Duboeuf F, Davignon JL, Norman DD, Isaac S, Marotte H, Tigyi G, Machuca-Gayet I, Coury F. (2019) Osteoclast-derived Autotaxin, a distinguishing factor for inflammatory bone loss. Arthritis & Rheumatology. 71(11): 1801-1811.
9. Coury F, Peyruchaud O and Machuca-Gayet I. (2019). Osteoimmunology of bone loss in inflammatory rheumatic diseases. Frontiers in Immunology. 10:679. doi: 10.3389.  IF: 5.5
10. Leblanc R, Sahay D, Houssin A, Irma Machuca-Gayet I, Peyruchaud O. (2018) Autotaxin-β interaction with the cell surface via syndecan-4 impacts on cancer cell proliferation and metastasis. Oncotarget. 9 (69): 33170-33185.